Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update

Abeona Therapeutics Inc (NASDAQ:ABEO) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,990,000 shares, a growth of 17.1% from the March 15th total of 1,700,000 shares. Currently, 7.7% of the shares of the company are sold short. Based on an average daily trading volume, of 333,800 shares, the days-to-cover ratio is currently 6.0 days.

Insider Buying and Selling

In related news, Director Mark Alvino sold 7,084 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $5.11, for a total value of $36,199.24. Following the transaction, the director now directly owns 62,816 shares of the company’s stock, valued at approximately $320,989.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.30% of the stock is owned by insiders.

Institutional Trading of Abeona Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp raised its holdings in shares of Abeona Therapeutics by 5.2% during the third quarter. Northern Trust Corp now owns 108,647 shares of the biopharmaceutical company’s stock valued at $457,000 after acquiring an additional 5,412 shares in the last quarter. State Street Corp boosted its position in shares of Abeona Therapeutics by 18.0% during the second quarter. State Street Corp now owns 51,095 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 7,800 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of Abeona Therapeutics during the third quarter valued at $43,000. GSA Capital Partners LLP purchased a new position in Abeona Therapeutics in the third quarter worth about $49,000. Finally, Bank of New York Mellon Corp purchased a new position in Abeona Therapeutics in the second quarter worth about $52,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Trading Down 3.1 %

Shares of NASDAQ ABEO opened at $7.55 on Friday. Abeona Therapeutics has a 12 month low of $2.73 and a 12 month high of $9.01. The firm has a market capitalization of $206.49 million, a price-to-earnings ratio of -2.93 and a beta of 1.49. The business has a 50-day moving average of $7.20 and a 200-day moving average of $5.49.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.13). On average, analysts predict that Abeona Therapeutics will post -1.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, February 19th.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.